Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 6/20 | 0.63 |
| ▸ | PIN1 | Q13526 | 6/20 | 0.63 |
| ▸ | CDK1 | P06493 | 3/20 | 0.63 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.63 |
| ▸ | CDK2 | P24941 | 3/20 | 0.63 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MPO | P05164 | 6/20 | 0.59 |
| ▸ | TPO | P07202 | 1/20 | 0.59 |
| ▸ | EPX | P11678 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-O-Benzylguanine SCHEMBL29405347 | 1.00 | MGMT (0.63) | MGMTPIN1CDK1CCNB1CCNA2 | |
| 6-O-Benzylguanine SCHEMBL4631743 | 0.99 | MGMT (0.61) | MGMTPIN1CDK1CCNB1CCNA2 | |
| 6-O-Benzylguanine SCHEMBL4869637 | 0.94 | MGMT (0.56) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL3720508 | 0.87 | MGMT (0.52) | MGMTPIN1CDK1CCNB1CCNA2 | |
| 6-O-Benzylguanine SCHEMBL10916356 | 0.87 | PIN1 (0.50) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL21036999 | 0.86 | PIN1 (0.51) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL15372394 | 0.86 | PIN1 (0.64) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL1533391 | 0.86 | MPO (0.61) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL13064122 | 0.85 | MGMT (0.67) | MGMTPIN1CDK1CCNB1CCNA2 | |
| SCHEMBL27090535 | 0.85 | PIN1 (0.47) | MGMTPIN1CDK1CCNB1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852236-A | Entecavir a synthetic intermediate of (C) preparation method of entecavir | 南京工业大学 | 2024-10-29 | — | — | CN | claimed |
| CN-108371662-A | A kind of application of five-ring heterocycles miazines compound | 中国药科大学 | 2018-08-07 | — | — | CN | claimed |
| CN-101781301-B | Method for preparing entecavir | UNIV FUDAN | 2013-04-10 | — | — | CN | claimed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | claimed |
| JP-4726491-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| EP-1492791-B1 | CRYSTAL AND SOLVATE OF 2-AMINO-6-BENZYLOXYPURINE AND PRODUCTION METHODS THEREOF | SUMITOMO CHEMICAL CO (JP) | 2008-06-04 | — | — | EP | claimed |
| US-7345170-B2 | Crystal and solvate of 2-amino-6-benzyloxypurine and production methods thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-18 | — | — | US | claimed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | claimed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | claimed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | claimed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | claimed |
| JP-2006509800-A | — | — | 2006-03-23 | — | — | JP | claimed |
| US-20050080098-A1 | Crystal and solvate of 2-amino-6-benzyloxypurine and production methods thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-14 | — | — | US | claimed |
| EP-1492791-A1 | CRYSTAL AND SOLVATE OF 2-AMINO-6-BENZYLOXYPURINE AND PRODUCTION METHODS THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-01-05 | — | — | EP | claimed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | claimed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2003084957-A1 | CRYSTAL AND SOLVATE OF 2-AMINO-6-BENZYLOXYPURINE AND PRODUCTION METHODS THEREOF | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-10-16 | — | — | WO | claimed |
| US-5064961-A | PROCESS FOR PREPARING AN OPTICALLY ACTIVE CYCLOBUTANE NUCLEOSIDE | E. R. SQUIBB & SONS, INC. (US) | 1991-11-12 | — | — | US | claimed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | claimed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | MGMT 1661/4885PIN1 4218/4885CDK1 1762/4885 |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | MGMT 1680/4885PIN1 4133/4885CDK1 1666/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | MGMT 1680/4885PIN1 4133/4885CDK1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.